News and reporting on lung cancer.
The study plans to recruit close to 300 patients with advanced non-small cell lung cancer, with half being treated based on liquid biopsy results.
A proof-of-principle study suggests metabolite clusters may differ in non-small cell lung cancer patients depending on tumor type, disease stage, and overall survival trajectory.
The company will market Inivata's InVision liquid biopsy assays to insured and self-pay patients across the region.
The World Health Organization has updated its list of essential medicines, Reuters reports.
Under the agreement, Biodesix will use the Thermo Fisher Ion Torrent Oncomine Pan-Cancer Cell-Free Assay to generate data to apply for FDA premarket approval.
The firm said it needs more time to ensure that the DetermaVu assay is providing the most consistent and sensitive results for patients.
At the WIN Symposium, a researcher from Sheba Medical Center discussed ongoing efforts to develop a 22-gene signature for predicting brain metastasis in NSCLC.
Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.
Almac said that the assay will be used in a clinical study of repotrectinib (TPX-0005), an investigational, next-generation tyrosine kinase inhibitor.
The project, established by the National Cancer Center of Japan, screens target genes in lung cancer to advance the development of new drugs and diagnostics.
23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.
By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.
NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.
In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.